Emblica

Scientific Name(s): Phyllanthus emblica L. Family: Euphorbiaceae.

Common Name(s): Indian gooseberry , amalaki , anwala churna , emblic myrobalan , nelli , amalakam , sriphalam , gebrau chilicher , amlabaum , amla , ziphiyu-si , shabju , amlaj , amulch , toppinelli , ngop , an mole , yeowkan tse . Emblica is one of the constituents in the Ayurvedic preparations Triphala , Hyponidd , Kalpaamruthaa , and Chyavanprash .

Uses

Emblica exhibits strong antioxidant activity. It is one of the most important plants in the traditional Ayurvedic medical system as well as in other traditional health systems for immunomodulatory, anti-inflammatory, antiulcer, hepatoprotective, and anticancer actions. However, there is very limited clinical evidence to support the use of emblica for any indication.

Dosing

There are few clinical studies to guide dosages. Diabetes/hyperlipidemia : 1 to 3 g of powdered, dried fruit was consumed daily in 30 mL of water for 21 days in 1 clinical trial. Another trial used amla 300 mg tablets (each containing 50% amla extract and 50% dextrin) 3 times per day.

Contraindications

Contraindications have not been identified.

Pregnancy/Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Interactions

None well documented.

Adverse Reactions

Research reveals little or no information regarding adverse reactions with the use of this product.

Toxicology

No major toxicities have been reported.

Botany

Emblica is a small to medium-sized deciduous tree native to tropical southeastern Asia. Its leaves are simple, feather-like, and closely set along the branchlets. Flowers are green-yellow, and the round, greenish-yellow fruits are smooth and hard in appearance. The fruits, which ripen in autumn and are harvested by hand, are commonly used in the Indian diet. 1 , 2 , 3 A common synonym is Emblica officinalis Gaertn.

History

A method of emblica preparation was described in the first century AD in Sanskrit. Records of the medicinal use of emblica also have been found in Arabic, Tibetan, and Egyptian texts, as well as in the Sidha (Indian), Ayurvedic, and Unani systems of medicine. All parts of the plant including the fruit, seed, leaves, root, bark, and flowers are used in both dried and fresh forms. In the Ayurvedic system, the amla fruit is noted for its light and dry qualities, as well as being cooling in energy. In India, the fruit is commonly eaten as a pickle. 2 , 3

Chemistry

The fruits contain a high concentration of ascorbic acid, which degrades with heating or cooking. In addition, they contain phenols, including ellagic acid, gallic acid, quercetin, kaempferol, corilagin, geraniin, furosin, gallotanins, emblicanins, flavonoids, glycosides, and proanthocyanidins. 4 , 5 , 6 , 7 , 8 , 9 , 10 The roots contain glycosides and tannins. 11 , 12

Most of the properties assigned to emblica are attributed to its strong antioxidant action. 8 , 13 , 14 , 15 , 16 The ascorbic acid content of the fruit has been assayed at approximately 1 g per 100 mL of fresh fruit juice and accounts for 45% to 70% of the antioxidant activity. 17 The Ayurvedic process of preparing the amla berry results in a 3-fold increase of ascorbic acid and an increase in the concentration of polyphenols. This dried fruit powder is mixed with fresh emblica juice for a few hours, and then dried and powdered again. Repeated up to 21 times, this method of fruit processing is nutritionally beneficial. 17 Other compounds having antioxidant properties include the emblicanins, gallic acid, methyl gallate, corilagin, furosin, and geraniin. 6 , 17 , 18

Uses and Pharmacology

Few quality controlled clinical trials are documented despite the widespread use of emblica in traditional health systems.

Anti-inflammatory effects
Animal data

Animal models of acute and chronic inflammation show limited anti-inflammatory effects, with reduced edema and granulomatous tissue at higher dosages. 19 , 20

Clinical data

Research reveals no clinical trial data on the use of emblica as an anti-inflammatory agent. However, in vitro studies using bronchial epithelial cells extracted from a patient with cystic fibrosis demonstrated inhibition of pro-inflammatory cytokine expression. 21 Inhibition of collagenase and hyaluronidase by dried emblica fruit extract using donor cartilage from osteoarthritic patients was also demonstrated in vitro. 22 Crude extracts have also induced apoptotic cell death of mature osteoclasts without affecting osteoclastogenesis, possibly via modulation of transcription factors. 23 , 24

Antimicrobial effects
In vitro studies

Alcoholic and aqueous extracts of emblica showed positive results against common human pathogens, including bacteria, viruses, and fungi. Activity appears to be stronger against gram-positive bacteria, and only limited efficacy against fungi. 25 , 26 , 27 , 28 Activity against herpes simplex viruses 1 and 2 has been attributed to the phenolic content, 29 while activity against the coxsackie virus was found for phyllaemblicin B extracted from the roots of the plant. 30 , 31

Animal data

Induced Klebsiella pneumoniae in mice responded in the long term (30 days) to dietary supplementation with powdered fruit. However, colonization was not prevented in the short term (15 days). 32

Clinical data

Research reveals no clinical data regarding the use of emblica as an antimicrobial agent.

Cancer

Much interest surrounds the potential for emblica use in treating cancer; however, there are no published clinical trials or epidemiological data.

Animal data

In response to heavy metal carcinogens (arsenic, chromium, nickel), rats given emblica extracts showed a reduction in the number of chromosomal aberrations, number of damaged cells, frequency of micronuclei in bone marrow cells, free radical production, and increased cell survival. 33 , 34 , 35 , 36 Rodents fed emblica extracts showed an increase in activity of natural killer cells, antibody-dependent cellular cytotoxicity, and survival in response to tumor cells (lymphoma and mammary carcinoma). 37 , 38 , 39 In 1 of these experiments, there was no effect on tumor development, but a decrease in tumor volume was shown. 33 Cytotoxicity to tumor cells has been demonstrated by organic acid gallates and hydrolysable tannins. 7 One report has been published in which emblica had no effect in reducing lung cancer parameters in mice. 40 Emblica extracts protected irradiated mice from radiation sickness, increased the 30-day survival rate, and decreased total mortality. 41 , 42 , 43

Clinical data

Research reveals no clinical trial data regarding the use of emblica in cancerous conditions. However, in vitro studies using human cancer cell lines including lung, liver, cervical, ovarian, and breast cells have been conducted. 44 , 45 , 46 , 47 Various extracts of emblica inhibited hepatocarcinogenesis as measured by parameters such as tumor incidence, enzyme measurements, and other liver injury markers. 37 , 48 , 49 , 50 , 51

Dermatology
Animal data

Animal experiments have been conducted, as well as in vitro studies using human skin fibroblasts demonstrating increased cell proliferation and collagen production at wound and ultraviolet B light (UBV) photo-aged sites. 52 , 53 , 54

Clinical data

Limited clinical studies have been conducted using emblica extracts in combination with other agents in skin-lightening creams as an alternative to hydroquinone. 55

GI effects
Animal data

Alcoholic and aqueous extracts of emblica have shown protective and healing effects in induced gastric ulcers in animal experiments. 56 , 57 , 58 One experiment, however, established a biphasic effect with healing observed at lower doses of ethanolic fruit extracts and ulceration evident on histology with higher doses. 59

In vitro studies using rodent jejunum and ileum as well as in live mice show antidiarrheal and spasmolytic effects on castor oil-induced diarrhea, possibly due to muscarinic action and calcium channel blockade. 60

Clinical data

Research reveals no clinical data regarding the use of emblica in gastric ulcers or diarrhea.

Hepato- and renal-protective effects
Animal data

Alcoholic and aqueous extracts of emblica fruits have shown hepatoprotective properties in experiments in rats. Hepatic insults include antituberculosis drugs, arsenic, ethanol, thiacetamide, carbon tetrachloride, and cyclophosphamide. The experiments demonstrated histological and/or enzymatic protective and restorative effects. A decreased severity of hepatic fibrosis was also demonstrated, and some studies included improved renal and pancreatic indices. 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71

Clinical data

Research reveals no clinical data regarding the use of emblica in renal disease; however, in patients with uremia consequent to end-stage renal disease (ESRD), emblica reduced markers of oxidative stress. No effect on hepatic, renal, or diabetic indices was observed. 72

Hyperlipidemia
Animal data

A number of animal experiments report improved lipid profiles. 73 , 74 , 75 Flavonoid extracts from the fruits of emblica inhibited synthesis and enhanced degradation of cholesterol via increased hepatic HMG-CoA reductase. 10 Fresh emblica fruit juice administered to rabbits resulted in induced aortic plaques regressing to near normal, while serum and tissue lipids decreased, 76 and ethanol extract of emblica improved the lipid profile, as well as reduced hypertension in induced metabolic syndrome in rats. 74

Clinical data

In a human clinical trial, healthy and hypercholesterolemic men (35 to 55 years of age) given emblica supplementation for 28 days experienced a decrease in serum cholesterol levels. The condition was reversible upon discontinuation of the supplement. 77 In volunteers with and without type 2 diabetes, 2 to 3 g daily of powdered, dried emblica fruit improved the lipid profile (decreased total cholesterol, low-density lipoprotein, and triglycerides; increased high-density lipoprotein) at 21 days. Only among the volunteers with diabetes was there a decrease in total lipids at the 3 g daily dose. 78

Diabetes
Animal data

In single- and multidose experiments, emblica decreased blood glucose levels in rats with an induced diabetic state. 13 , 14 , 15 , 73 Triphala (a mixed herbal preparation containing emblica) showed a stronger effect than emblica alone, 79 and another mixed preparation reduced blood glucose in a manner similar to that of glibenclamide. 14 Serum creatinine was reduced, and serum albumin increased within 20 days in rats fed emblica. 14 In rats with induced diabetes, neuropathic pain was reduced with supplemental emblica possibly via an antioxidative mechanism. 80 In vitro studies also suggest inhibition of alpha-amylase and glucosidase as potential mechanisms. 81 However, in another study in rats with diabetes, dried fruits did not prevent hyperglycemia despite delaying cataract progression. 82

Clinical data

Decreases in fasting and 2-hour postprandial serum glucose were demonstrated in a clinical study using both healthy and type 2 diabetic volunteers. One to 3 g of powdered, dried fruit was consumed daily in 30 mL of water for 21 days. 78 In another study in patients with ESRD and uremia, no effect on diabetic indices was observed. 72

Other effects
Analgesic/Antipyretic

Alcohol and aqueous extracts of emblica fruit were tested for analgesic and antipyretic activity in mice. Results were similar to those of aspirin, except for response to heat pain model in which emblica had no activity. 83

Antitussive

An alcoholic extract of the fruits showed a dose-dependent effect similar to that of dropropizine in cats, but was less active than codeine. 84

Antivenom

An alcoholic extract of emblica roots showed neutralizing capacity against the hemorrhagic action of snake venom in mice. 85

Cardiac effects

The emblica fruits showed a protective effect against ischemic reperfusion injury in rats. 86 In another study, the emblicanins were demonstrated to prevent oxidative stress. 9

CNS

Studies in rats have demonstrated improved memory and reversal of drug-induced amnesia with the Ayurvedic preparation anwala churna. 87 , 88 Aqueous fruit extract exerted a protective effect on alcohol-induced brain mitochondrial dysfunction in rats. 89

Immune

Rats exposed to noise stress for 15 days and given Triphala showed an increased neutrophil function and lowered cortisone release. 90 However, in another experiment, an aqueous extract of emblica fruits had no effect on cold stress-induced cortisone release. 91

Ophthalmic

Emblica is one component of a mixed herbal eye drop formulation ( Ophthacare ) that showed activity in mild infections and inflammatory eye conditions in a clinical study; however, the quality of study methodology was limited. 92

Spermatotoxicity

Sperm count, motility, and viability were increased in mice and in human sperm with ripe emblica fruit extract. 93

Dosage

There are few clinical studies to guide dosage.

Diabetes/hyperlipidemia

1 to 3 g of powdered, dried fruit was consumed daily in 30 mL of water for 21 days in 1 clinical trial. 78 Another trial used amla 300 mg tablets (each containing 50% amla extract and 50% dextrin) 3 times per day. 72

A dose of 3 to 6 g/day of powdered emblica has been extrapolated from a vitamin C 1 g/day dose. 36

Another report suggests a content of vitamin C 1,100 to 1,700 mg per 100 g fruit extract. 72

Pregnancy/Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Interactions

None well documented.

Adverse Reactions

Research reveals little or no information regarding adverse reactions with the use of this product. Experiments in animals have shown no reported adverse reactions.

Toxicology

No major reported toxicities have been associated with the fruit. In toxicity studies in rats, no toxicity was observed in single- or longer-term–dose administration. Additionally, no detrimental effect was noted on liver or renal function. 91 No chromosomal aberrations were found following 7- and 14-day treatment regimens in rats with crude fruit extract. 48 In another experiment, no toxicity or mutagenicity were observed in rats even at the highest doses. 44

Bibliography

1. Phyllanthus emblica L. USDA, NRCS. 2007. PLANTS database. ( http://plants.usda.gov . August 2006). National Plant Data Team, Greensboro, NC 27401-4901 USA.
2. Shanmugasundaram KR, Seethapathy PG, Shanmugasundaram ER. Anna Pavala Sindhooram–an antiatherosclerotic Indian drug. J Ethnopharmacol . 1983;7(3):247-265.
3. Unander DW, Webster GL, Blumberg BS. Records of usage or assays in Phyllanthus ( Euphorbiaceae ). I. Subgenera Isocladus , Kirganelia , Cicca and Emblica . J Ethnopharmacol . 1990;30(3):233-264.
4. Nisha P, Singhal RS, Pandit AB. A study on degradation kinetics of ascorbic acid in amla ( Phyllanthus emblica L .) during cooking. Int J Food Sci Nutr . 2004;55(5):415-422.
5. Zhang YJ, Abe T, Tanaka T, Yang CR, Kouno I. Phyllanemblinins A-F, new ellagitannins from Phyllanthus emblica . J Nat Prod . 2001;64(12):1527-1532.
6. Kumaran A, Karunakaran RJ. Nitric oxide radical scavenging active components from Phyllanthus emblica L. Plant Foods Hum Nutr . 2006;61(1):1-5.
7. Zhang YJ, Nagao T, Tanaka T, Yang CR, Okabe H, Kouno I. Antiproliferative activity of the main constituents from Phyllanthus emblica . Biol Pharm Bull . 2004;27(2):251-255.
8. Bajpai M, Pande A, Tewari SK, Prakash D. Phenolic contents and antioxidant activity of some food and medicinal plants. Int J Food Sci Nutr . 2005;56(4):287-291.
9. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Effect of bioactive tannoid principles of Emblica officinalis on ischemia-reperfusion-induced oxidative stress in rat heart. Phytomedicine . 2002;9(2):171-174.
10. Anila L, Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica -effectiveness for dyslipidemia. J Ethnopharmacol . 2002;79(1):81-87.
11. Zhang YJ, Tanaka T, Iwamoto Y, Yang CR, Kouno I. Novel norsesquiterpenoids from the roots of Phyllanthus emblica . J Nat Prod . 2000;63(11):1507-1510.
12. Zhang YJ, Tanaka T, Iwamoto Y, Yang CR, Kouno I. Novel sesquiterpenoids from the roots of Phyllanthus emblica . J Nat Prod . 2001;64(7):870-873.
13. Babu PS, Stanely Mainzen Prince P. Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats. J Pharm Pharmacol . 2004;56(11):1435-1442.
14. Rao TP, Sakaguchi N, Juneja LR, Wada E, Yokozawa T. Amla ( Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food . 2005;8(3):362-368.
15. Naik GH, Priyadarsini KI, Bhagirathi RG, et al. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. Phytother Res . 2005;19(7):582-586.
16. Naik GH, Priyadarsini KI, Mohan H. Evaluating the antioxidant activity of different plant extracts and herbal formulations. Res Chem Intermed . 2005;31(1-3):145-151.
17. Poltanov EA, Shikov AN, Dorman HJ, et al. Chemical and antioxidant evaluation of Indian gooseberry ( Emblica officinalis Gaertn., syn. Phyllanthus emblica L.) supplements. Phytother Res . 2009;23(9):1309-1315.
18. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol . 2000;71(1-2):23-43.
19. Dang GK, Parekar RR, Kamat SK, Scindia AM, Rege NN. Antiinflammatory activity of Phyllanthus emblica , Plumbago zeylanica and Cyperus rotundus in acute models of inflammation. Phytother Res . 2011;25(6):904-908.
20. Muthuraman A, Sood S, Singla SK. The antiinflammatory potential of phenolic compounds from Emblica officinalis L. in rat. Inflammopharmacology . 2010 Jul 2. [Epub ahead of print]
21. Nicolis E, Lampronti I, Dechecchi MC, et al. Pyrogallol, an active compound from the medicinal plant Emblica officinalis , regulates expression of pro-inflammatory genes in bronchial epithelial cells. Int Immunopharmacol . 2008;8(12):1672-1680.
22. Sumantran VN, Kulkarni A, Chandwaskar R, et al. Chondroprotective potential of fruit extracts of Phyllanthus emblica in osteoarthritis. Evid Based Complement Alternat Med. 2008;5(3):329-335.
23. Piva R, Penolazzi L, Borgatti M, et al. Apoptosis of human primary osteoclasts treated with molecules targeting nuclear factor-kappaB. Ann N Y Acad Sci . 2009;1171:448-456.
24. Penolazzi L, Lampronti I, Borgatti M, et al. Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis . BMC Complement Altern Med . 2008;8:59.
25. Rani P, Khullar N. Antimicrobial evaluation of some medicinal plants for their anti-enteric potential against multi-drug resistant Salmonella typhi . Phytother Res . 2004;18(8):670-673.
26. Dutta BK, Rahman I, Das TK. Antifungal activity of Indian plant extracts. Mycoses . 1998;41(11-12):535-536.
27. Rahman S, Akbor MM, Howlader A, Jabbar A. Antimicrobial and cytotoxic activity of the alkaloids of Amlaki ( Emblica officinalis ). Pak J Biol Sci . 2009;12(16):1152-1155.
28. Liu X, Zhao M, Luo W, Yang B, Jiang Y. Identification of volatile components in Phyllanthus emblica L. and their antimicrobial activity. J Med Food . 2009;12(2):423-428.
29. Xiang Y, Pei Y, Qu C, et al. In vitro Anti-Herpes Simplex Virus Activity of 1,2,4,6-Tetra-O-galloyl-beta-d-glucose from Phyllanthus emblica L. ( Euphorbiaceae ). Phytother Res . 2011 Jan 7. 10.1002/ptr.3368 . [Epub ahead of print]
30. Liu Q, Wang YF, Chen RJ, et al. Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica . J Nat Prod . 2009;72(5):969-972.
31. Wang YF, Wang XY, Ren Z, et al. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis. Antiviral Res . 2009;84(2):150-158.
32. Saini A, Sharma S, Chhibber S. Protective efficacy of Emblica officinalis against Klebsiella pneumoniae induced pneumonia in mice. Indian J Med Res . 2008;128(2):188-193.
33. Biswas S, Talukder G, Sharma A. Protection against cytotoxic effects of arsenic by dietary supplementation with crude extract of Emblica officinalis fruit. Phytother Res . 1999;13(6):513-516.
34. Sai Ram M, Neetu D, Deepti P, et al. Cytoprotective activity of Amla ( Emblica officinalis ) against chromium (VI) induced oxidative injury in murine macrophages. Phytother Res . 2003;17(4):430-433.
35. Sai Ram M, Neetu D, Yogesh B, et al. Cyto-protective and immunomodulating properties of Amla ( Emblica officinalis ) on lymphocytes: an in-vitro study. J Ethnopharmacol . 2002;81(1):5-10.
36. Dhir H, Agarwal K, Sharma A, Talukder G. Modifying role of Phyllanthus emblica and ascorbic acid against nickel clastogenicity in mice. Cancer Lett. 1991;26;59(1):9-18.
37. Jeena KJ, Joy KL, Kuttan R. Effect of Emblica officinalis , Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Lett . 1999;136(1):11-16.
38. Suresh K, Vasudevan DM. Augmentation of murine natural killer cell and antibody dependent cellular cytotoxicity activities by Phyllanthus emblica , a new immunomodulator. J Ethnopharmacol . 1994;44(1):55-60.
39. Veena K, Shanthi P, Sachdanandam P. Anticancer effect of Kalpaamurthaa on mammary carcinoma in rats with reference to glycoprotein components, lysosomal and marker enzymes. Biol Pharm Bull . 2006:29(3):565-569.
40. Menon LG, Kuttan R, Kuttan G. Effect of rasayanas in the inhibition of lung metastasis induced by B16F-10 melanoma cells. J Exp Clin Cancer Res . 1997;16(4):365-368.
41. Singh I, Sharma A, Nunia V, Goyal PK. Radioprotection of Swiss albino mice by Emblica officinalis . Phytother Res . 2005;19(5):444-446.
42. Jagetia GC, Baliga MS, Malagi KJ, Kamath M. The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation. Phytomedicine . 2002;9(2):99-108.
43. Jindal A, Soyal D, Sharma A, Goyal PK. Protective effect of an extract of Emblica officinalis against radiation-induced damage in mice. Integr Cancer Ther . 2009;8(1):98-105.
44. Sharma N, Trikha P, Athar M, Raisuddin S. In vitro inhibition of carcinogen-induced mutagenicity by Cassia occidentalis and Emblica officinalis . Drug Chem Toxicol . 2000;23(3):477-484.
45. Arora S, Kaur K, Kaur S. Indian medicinal plants as a reservoir of protective phytochemicals. Teratog Carcinog Mutagen . 2003;(suppl 1):295-300.
46. Yang CJ, Wang CS, Hung JY, et al. Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model. Lung Cancer . 2009;66(2):162-168.
47. Ngamkitidechakul C, Jaijoy K, Hansakul P, Soonthornchareonnon N, Sireeratawong S. Antitumour effects of Phyllanthus emblica L.: induction of cancer cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells. Phytother Res . 2010;24(9):1405-1143.
48. Jose JK, Kuttan G, Kuttan R. Antitumour activity of Emblica officinalis . J Ethnopharmacol . 2001;75(2-3):65-69.
49. Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C. Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol . 2008;14(10):1491-1497.
50. Zhong ZG, Wu DP, Huang JL, et al. Progallin A isolated from the acetic ether part of the leaves of Phyllanthus emblica L . induces apoptosis of human hepatocellular carcinoma BEL-7404 cells by up-regulation of Bax expression and down-regulation of Bcl-2 expression. J Ethnopharmacol . 2011;133(2):765-772.
51. Sultana S, Ahmed S, Jahangir T. Emblica officinalis and hepatocarcinogenesis: a chemopreventive study in Wistar rats. J Ethnopharmacol . 2008:19;118(1):1-6.
52. Sumitra M, Manikandan P, Gayathri VS, Mahendran P, Suguna L. Emblica officinalis exerts wound healing action through up-regulation of collagen and extracellular signal-regulated kinases (ERK1/2). Wound Repair Regen . 2009;17(1):99-107.
53. Fujii T, Wakaizumi M, Ikami T, Saito M. Amla ( Emblica officinalis Gaertn.) extract promotes procollagen production and inhibits matrix metalloproteinase-1 in human skin fibroblasts. J Ethnopharmacol . 2008;119(1):53-57.
54. Adil MD, Kaiser P, Satti NK, Zargar AM, Vishwakarma RA, Tasduq SA. Effect of Emblica officinalis (fruit) against UVB-induced photo-aging in human skin fibroblasts. J Ethnopharmacol . 2010;132(1):109-114.
55. Costa A, Moisés TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol . 2010;85(5):613-620.
56. Al-Rehaily AJ, Al-Howiriny TA, Al-Sohaibani MO, Rafatullah S. Gastroprotective effects of “Amla” Emblica officinalis on in vivo test models in rats. Phytomedicine . 2002;9(6):515-522.
57. Sairam K, Rao ChV, Babu MD, Kumar KV, Agrawal VK, Goel RK. Antiulcerogenic effect of methanolic extract of Emblica officinalis : an experimental study. J Ethnopharmacol . 2002;82(1):1-9.
58. Bandyopadhyay SK, Pakrashi SC, Pakrashi A. The role of antioxidant activity of Phyllanthus emblica fruits on prevention from indomethacin induced gastric ulcer. J Ethnopharmacol . 2000;70(2):171-176.
59. Chatterjee A, Chattopadhyay S, Bandyopadhyay SK. Biphasic Effect of Phyllanthus emblica L . Extract on NSAID-Induced Ulcer: An Antioxidative Trail Weaved with Immunomodulatory Effect. Evid Based Complement Alternat Med . 2011;2011:146808. Epub 2010 Nov 7.
60. Mehmood MH, Siddiqi HS, Gilani AH. The antidiarrheal and spasmolytic activities of Phyllanthus emblica are mediated through dual blockade of muscarinic receptors and Ca2+ channels. J Ethnopharmacol . 2011;133(2):856-865.
61. Tasduq SA, Kaisar P, Gupta DK, et al. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity. Phytother Res . 2005;19(3):193-197.
62. Tasduq SA, Mondhe DM, Gupta DK, Baleshwar M, Johri RK. Reversal of fibrogenic events in liver by Emblica officinalis (fruit), an Indian natural drug. Biol Pharm Bull. 2005;28(7):1304-1306.
63. Haque R, Bin-Hafeez B, Ahmad I, Parvez S, Pandey S, Raisuddin S. Protective effects of Emblica officinalis Gaertn. in cyclophosphamide-treated mice. Hum Exp Toxicol . 2001;20(12):643-650.
64. Jose JK, Kuttan R. Hepatoprotective activity of Emblica officinalis and Chyavanaprash. J Ethnopharmacol . 2000;72(1-2):135-140.
65. Sultana S, Ahmed S, Sharma S, Jahangir T. Emblica officinalis reverses thioacetamide-induced oxidative stress and early promotional events of primary hepatocarcinogenesis. J Pharm Pharmacol . 2004;56(12):1573-1579.
66. Pramyothin P, Samosorn P, Poungshompoo S, Chaichantipyuth C. The protective effects of Phyllanthus emblica Linn. extract on ethanol induced rat hepatic injury. J Ethnopharmacol . 2006;107(3):361-364.
67. Verma R, Chakraborty D. Alterations in DNA, RNA and protein contents in liver and kidney of mice treated with ochratoxin and their amelioration by Emblica officinalis aqueous extract. Acta Pol Pharm . 2008;65(1):3-9.
68. Chakraborty D, Verma R. Ameliorative effect of Emblica officinalis aqueous extract on ochratoxin-induced lipid peroxidation in the kidney and liver of mice. Int J Occup Med Environ Health . 2010;23(1):63-73.
69. Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic induced oxidative stress in Swiss albino mice. Chem Biol Interact . 2009;180(1):20-30.
70. Reddy VD, Padmavathi P, Varadacharyulu NCh. Emblica officinalis protects against alcohol-induced liver mitochondrial dysfunction in rats. J Med Food . 2009;12(2):327-333.
71. Sidhu S, Pandhi P, Malhotra S, Vaiphei K, Khanduja KL. Beneficial effects of Emblica officinalis in L-arginine-induced acute pancreatitis in rats. J Med Food . 2011;14(1-2):147-155.
72. Chen TS, Liou SY, Chang YL. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med . 2009;37(1):19-25.
73. Anila L, Vijayalakshmi NR. Beneficial effects of flavonoids from Sesamum indicum , Emblica officinalis and Momordica charantia . Phytother Res . 2000;14(8):592-595.
74. Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla ( Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr . 2010;103(4):502-512.
75. Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu DC, Juneja LR. Amla ( Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr . 2007;97(6):1187-1195.
76. Mathur R, Sharma A, Dixit VP, Varma M. Hypolipidaemic effect of fruit juice of Emblica officinalis in cholesterol-fed rabbits. J Ethnopharmacol . 1996;50(2):61-68.
77. Jacob A, Pandey M, Kapoor S, Saroja R. Effect of the Indian gooseberry (amla) on serum cholesterol levels in men aged 35-55 years. Eur J Clin Nutr. 1988;42(11):939-944.
78. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit ( Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr . 2011 Apr 18. [Epub ahead of print]
79. Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol . 2002;81(2):155-160.
80. Tiwari V, Kuhad A, Chopra K. Emblica officinalis Corrects Functional, Biochemical and Molecular Deficits in Experimental Diabetic Neuropathy by Targeting the Oxido-nitrosative Stress Mediated Inflammatory Cascade. Phytother Res . 2011 Mar 11. 10.1002/ptr.3440 . [Epub ahead of print]
81. Nampoothiri SV, Prathapan A, Cherian OL, Raghu KG, Venugopalan VV, Sundaresan A. In vitro antioxidant and inhibitory potential of Terminalia bellerica and Emblica officinalis fruits against LDL oxidation and key enzymes linked to type 2 diabetes. Food Chem Toxicol . 2011;49(1):125-131.
82. Suryanarayana P, Saraswat M, Petrash JM, Reddy GB. Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol Vis . 2007;13:1291-1297.
83. Perianayagam JB, Sharma SK, Joseph A, Christina AJ. Evaluation of anti-pyretic and analgesic activity of Emblica officinalis Gaertn. J Ethnopharmacol . 2004;95(1):83-85.
84. Nosál'ová G, Mokrý J, Hassan KM. Antitussive activity of the fruit extract of Emblica officinalis Gaertn. (Euphorbiaceae). Phytomedicine . 2003;10(6-7):583-589.
85. Alam MI, Gomes A. Snake venom neutralization by Indian medicinal plants ( Vitex negundo and Emblica officinalis ) root extracts. J Ethnopharmacol . 2003;86(1):75-80.
86. Rajak S, Banerjee SK, Sood S, et al. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. Phytother Res . 2004;18(1):54-60.
87. Vasudevan M, Parle M. Effect of Anwala churna ( Emblica officinalis GAERTN.): an ayurvedic preparation on memory deficit rats. Yakugaku Zasshi . 2007;127(10):1701-1707.
88. Vasudevan M, Parle M. Memory enhancing activity of Anwala churna ( Emblica officinalis Gaertn.): an Ayurvedic preparation. Physiol Behav . 2007;91(1):46-54.
89. Reddy VD, Padmavathi P, Kavitha G, Gopi S, Varadacharyulu N. Emblica officinalis ameliorates alcohol-induced brain mitochondrial dysfunction in rats. J Med Food . 2011;14(1-2):62-68.
90. Srikumar R, Parthasarathy NJ, Manikaordan S, Narayanan GS, Sheeladevi R. Effect of Triphala on oxidative stress and on cell-mediated immune response against noise stress in rats. Mol Cell Biochem . 2006;283(1-2):67-74.
91. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res . 1999;13(4):275-291.
92. Biswas NR, Gupta SK, Das GK, et al. Evaluation of Ophthacare eye drops — a herbal formulation in the management of various ophthalmic disorders. Phytother Res . 2001;15(7):618-620.
93. Chakraborty D, Verma R. Spermatotoxic effect of ochratoxin and its amelioration by Emblica officinalis aqueous extract. Acta Pol Pharm . 2009;66(6):689-695.

Copyright © 2009 Wolters Kluwer Health

Hide
(web2)